HYLN

Hyliion is not yet a business — it is a bet on the KARNO Power Module, which the 10-K confirms is still pre-commercial ("Through December 31, 2025, we have not yet commercialized the KARNO Power Module"). All $3.48M of FY2025 revenue is best-effort, cost-plus R&D services for the U.S. government (ONR/Navy), booked at essentially breakeven: $3.31M cost of revenue against $3.48M revenue for just $170K of gross profit (4.9% margin). Against that, the company ran a $65.6M operating loss and burned $46.5M in operating cash plus $23.7M of capex. At a $768M market cap the stock trades at 221x sales — a valuation that only makes sense if you fully underwrite a commercialization event the filing itself describes as still ahead of it.

The balance sheet is the redeeming feature and the reason this is a 'sell' rather than an 'avoid': liabilities are just $11.6M against $192M of equity (0.06x), there is effectively no debt, and current assets of $98.6M dwarf $9.86M of current liabilities. But cash is only $22.9M, and combined operating-plus-capital burn of roughly $70M/year means the liquidity buffer is thin relative to the spend. Management is explicit that more capital is coming: they "anticipate that, at some time, we will seek additional sources of capital" and want to be "deliberate and opportunistic" about the "timing and structure of a capital raise." On 178M shares and a deficit that has grown to -$207M in accumulated losses, dilution is a when-not-if overhang.